Demant (DEMANT) Status Update summary
Event summary combining transcript, slides, and related documents.
Status Update summary
14 Oct, 2026Oticon More technology
Oticon More is the first hearing aid with an on-board Deep Neural Network, trained on 12 million real-life sound scenes and built for real-time operation.
Powered by the Polaris chipset, with 8x the memory and 2x the processing power of Velox S; delivers 30% more information to the brain than Oticon Opn S, reduces listening effort and improves speech understanding by 15%.
Available in miniRITE rechargeable style, three upper price points and four power levels; supports iOS and compatible Android streaming and is prepared for Bluetooth LE Audio.
Multi-brand launches
Philips Hearing Solutions will launch the next-generation Philips HearLink family with AI sound technology, rechargeable batteries, iOS and compatible Android streaming, and Bluetooth LE Audio readiness.
Bernafon Alpha features Hybrid Technology that selects performance based on analysis of the listening situation; Sonic Radiant actively finds, filters and fine-tunes sound.
Oticon, Philips Hearing Solutions, Bernafon and Sonic flagship families will roll out in major markets over the coming weeks and months, across price points and power levels, based on miniRITE rechargeable technology.
Launch activity
Sales teams will hold local launch events, training sessions and marketing campaigns; a virtual live-streamed product event was scheduled for 30 November 2020.
Latest events from Demant
- Oticon Medical sale raises the 2022 EBIT outlook to DKK 3,600–3,900m.DEMANT
Investor Update - Recovery lifted hearing healthcare run rates, but 2020 guidance remained withdrawn.DEMANT
Status Update - Upgraded 2026 outlook after strong H1 growth, margin gains, and successful KIND and product launches.DEMANT
Q2 2026 - Q1 2026 saw 6% organic growth, strong Hearing Aids and Oticon Zeal momentum, and improved profitability.DEMANT
Q1 2026 - 2026 outlook: 3%-6% organic growth, DKK 4.1-4.5bn EBIT, cost savings, Zeal and KIND drive gains.DEMANT
Q4 2025 - Q3 organic growth reached 2%, driven by Hearing Care, with 2024 guidance reaffirmed.DEMANT
Q3 2024 - H1 2024 revenue up 4%, gross margin 76.8%, EBIT before special items down 4%.DEMANT
Q2 2024 - EUR 700M acquisition secures German leadership, with synergies and EPS accretion expected.DEMANT
M&A Announcement - 2025 outlook cut as US market weakness and FX headwinds hit growth and earnings.DEMANT
Q1 2025